TCR² Raises $125M to Move Ahead with Its Cell Therapy, CAR-T’s Cousin – Xconomy
|
TCR² Raises $125M to Move Ahead with Its Cell Therapy, CAR–T's Cousin
Xconomy TCR² Therapeutics has raised a $125 million Series B round to push ahead with live, cancer-fighting T cells. T cell receptor (TCR) therapies, the firm's area of focus, have not progressed as far as higher-profile CAR-T treatments, despite similarities … |
